Overview

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome

Status:
Recruiting
Trial end date:
2023-02-22
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals